Global Anti-Obesity Prescription Drugs Competitive Landscape Professional Research Report 2025
Description
Global Anti-Obesity Prescription Drugs Competitive Landscape Professional Research Report 2025
Research Summary
Anti-obesity prescription drugs are medications that are prescribed by doctors to people who are obese or overweight in order to help them lose weight by suppressing the appetite or reducing the absorption of fat in the body. These drugs work by changing the way the body processes food and nutrients, and may also cause changes in metabolism and energy levels. Some common anti-obesity prescription drugs include phentermine, liraglutide, orlistat, and Belviq. These drugs are typically used in combination with diet and exercise to achieve maximum weight loss results.
According to DIResearch's in-depth investigation and research, the global Anti-Obesity Prescription Drugs market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Anti-Obesity Prescription Drugs include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim, Alizyme etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Anti-Obesity Prescription Drugs. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Anti-Obesity Prescription Drugs market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Anti-Obesity Prescription Drugs market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Anti-Obesity Prescription Drugs industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Anti-Obesity Prescription Drugs Include:
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Anti-Obesity Prescription Drugs Product Segment Include:
Pediatric
Adult
Anti-Obesity Prescription Drugs Product Application Include:
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Anti-Obesity Prescription Drugs Industry PESTEL Analysis
Chapter 3: Global Anti-Obesity Prescription Drugs Industry Porter’s Five Forces Analysis
Chapter 4: Global Anti-Obesity Prescription Drugs Major Regional Market Size and Forecast Analysis
Chapter 5: Global Anti-Obesity Prescription Drugs Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Passenger Anti-Obesity Prescription Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Anti-Obesity Prescription Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Anti-Obesity Prescription Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Anti-Obesity Prescription Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Anti-Obesity Prescription Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Anti-Obesity Prescription Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Anti-Obesity Prescription Drugs Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents
170 Pages
- 1 Anti-Obesity Prescription Drugs Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Anti-Obesity Prescription Drugs Product by Type
- 1.2.1 Pediatric
- 1.2.2 Adult
- 1.3 Anti-Obesity Prescription Drugs Product by Application
- 1.3.1 Hospitals Pharmacies
- 1.3.2 Retail Pharmacies
- 1.3.3 E-commerce
- 1.4 Global Anti-Obesity Prescription Drugs Market Size Analysis (2020-2032)
- 1.5 Anti-Obesity Prescription Drugs Market Development Status and Trends
- 1.5.1 Anti-Obesity Prescription Drugs Industry Development Status Analysis
- 1.5.2 Anti-Obesity Prescription Drugs Industry Development Trends Analysis
- 2 Anti-Obesity Prescription Drugs Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Anti-Obesity Prescription Drugs Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Anti-Obesity Prescription Drugs Market Analysis by Regions
- 4.1 Anti-Obesity Prescription Drugs Overall Market: 2024 VS 2025 VS 2032
- 4.2 Global Anti-Obesity Prescription Drugs Revenue and Forecast Analysis (2020-2032)
- 4.2.1 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Region (2020-2025)
- 4.2.2 Global Anti-Obesity Prescription Drugs Revenue Forecast by Region (2026-2032)
- 5 Global Anti-Obesity Prescription Drugs Market Size by Type and Application
- 5.1 Global Anti-Obesity Prescription Drugs Market Size by Type (2020-2032)
- 5.2 Global Anti-Obesity Prescription Drugs Market Size by Application (2020-2032)
- 6 North America
- 6.1 North America Anti-Obesity Prescription Drugs Market Size and Growth Rate Analysis (2020-2032)
- 6.2 North America Key Manufacturers Analysis
- 6.3 North America Anti-Obesity Prescription Drugs Market Size by Type
- 6.4 North America Anti-Obesity Prescription Drugs Market Size by Application
- 6.5 North America Anti-Obesity Prescription Drugs Market Size by Country
- 6.5.1 US
- 6.5.2 Canada
- 7 Europe
- 7.1 Europe Anti-Obesity Prescription Drugs Market Size and Growth Rate Analysis (2020-2032)
- 7.2 Europe Key Manufacturers Analysis
- 7.3 Europe Anti-Obesity Prescription Drugs Market Size by Type
- 7.4 Europe Anti-Obesity Prescription Drugs Market Size by Application
- 7.5 Europe Anti-Obesity Prescription Drugs Market Size by Country
- 7.5.1 Germany
- 7.5.2 France
- 7.5.3 United Kingdom
- 7.5.4 Italy
- 7.5.5 Spain
- 7.5.6 Benelux
- 8 China
- 8.1 China Anti-Obesity Prescription Drugs Market Size and Growth Rate Analysis (2020-2032)
- 8.2 China Key Manufacturers Analysis
- 8.3 China Anti-Obesity Prescription Drugs Market Size by Type
- 8.4 China Anti-Obesity Prescription Drugs Market Size by Application
- 9 APAC (excl. China)
- 9.1 APAC (excl. China) Anti-Obesity Prescription Drugs Market Size and Growth Rate Analysis (2020-2032)
- 9.2 APAC (excl. China) Key Manufacturers Analysis
- 9.3 APAC (excl. China) Anti-Obesity Prescription Drugs Market Size by Type
- 9.4 APAC (excl. China) Anti-Obesity Prescription Drugs Market Size by Application
- 9.5 APAC (excl. China) Anti-Obesity Prescription Drugs Market Size by Country
- 9.5.1 Japan
- 9.5.2 South Korea
- 9.5.3 India
- 9.5.4 Australia
- 9.5.5 Southeast Asia
- 10 Latin America
- 10.1 Latin America Anti-Obesity Prescription Drugs Market Size and Growth Rate Analysis (2020-2032)
- 10.2 Latin America Key Manufacturers Analysis
- 10.3 Latin America Anti-Obesity Prescription Drugs Market Size by Type
- 10.4 Latin America Anti-Obesity Prescription Drugs Market Size by Application
- 10.5 Latin America Anti-Obesity Prescription Drugs Market Size by Country
- 10.5.1 Mexico
- 10.5.2 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Anti-Obesity Prescription Drugs Market Size and Growth Rate Analysis (2020-2032)
- 11.2 Middle East & Africa Key Manufacturers Analysis
- 11.3 Middle East & Africa Anti-Obesity Prescription Drugs Market Size by Type
- 11.4 Middle East & Africa Anti-Obesity Prescription Drugs Market Size by Application
- 11.5 Middle East & Africa Anti-Obesity Prescription Drugs Market Size by Country
- 11.5.1 Saudi Arabia
- 11.5.2 South Africa
- 12 Competition by Manufacturers
- 12.1 Global Anti-Obesity Prescription Drugs Market Revenue by Key Manufacturers (2021-2025)
- 12.2 Anti-Obesity Prescription Drugs Competitive Landscape Analysis and Market Dynamic
- 12.2.1 Anti-Obesity Prescription Drugs Competitive Landscape Analysis
- 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales
- 12.2.3 Market Dynamic
- 13 Key Companies Analysis
- 13.1 F Hoffmann La Roche Ltd
- 13.1.1 F Hoffmann La Roche Ltd Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
- 13.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.2 Orexigen Therapeutics
- 13.2.1 Orexigen Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.2.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
- 13.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.3 Novo Nordisk A/s
- 13.3.1 Novo Nordisk A/s Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
- 13.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.4 Arena Pharmaceuticals
- 13.4.1 Arena Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.4.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
- 13.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.5 Glaxosmithkline
- 13.5.1 Glaxosmithkline Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
- 13.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.6 Vivus
- 13.6.1 Vivus Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.6.2 Vivus Anti-Obesity Prescription Drugs Product Portfolio
- 13.6.3 Vivus Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.7 Boehringer Ingelheim
- 13.7.1 Boehringer Ingelheim Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
- 13.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.8 Alizyme
- 13.8.1 Alizyme Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.8.2 Alizyme Anti-Obesity Prescription Drugs Product Portfolio
- 13.8.3 Alizyme Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 14 Industry Chain Analysis
- 14.1 Anti-Obesity Prescription Drugs Industry Chain Analysis
- 14.2 Anti-Obesity Prescription Drugs Industry Raw Material and Suppliers Analysis
- 14.2.1 Anti-Obesity Prescription Drugs Key Raw Material Supply Analysis
- 14.2.2 Raw Material Suppliers and Contact Information
- 14.3 Anti-Obesity Prescription Drugs Typical Downstream Customers
- 14.4 Anti-Obesity Prescription Drugs Sales Channel Analysis
- 15 Research Findings and Conclusion
- 16 Methodology and Data Source
- 16.1 Methodology/Research Approach
- 16.2 Research Scope
- 16.3 Benchmarks and Assumptions
- 16.4 Date Source
- 16.4.1 Primary Sources
- 16.4.2 Secondary Sources
- 16.5 Data Cross Validation
- 16.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
